← Krystal Biotech, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $2k |
$8k
+300.00%
|
($4k)
-150.00%
|
$0
+100.00%
|
$0 | $50.7m |
$290.5m
+473.02%
|
$389.1m
+33.94%
|
$440.5m
+13.20%
|
|
| Cost of goods sold | $741k |
$3.2m
+332.93%
|
$7.8m
+141.99%
|
$15.6m
+101.26%
|
$17.9m
+14.77%
|
$0
-100.00%
|
$0 | $3.1m |
$20.1m
+548.38%
|
$23.0m
+14.89%
|
$23.6m
+2.46%
|
|
| Gross Profit (derived) | ($741k) |
($3.2m)
-332.93%
|
($7.8m)
-141.93%
|
($15.6m)
-101.21%
|
($17.9m)
-14.86%
|
$0
+100.00%
|
$0 | $47.6m |
$270.5m
+468.12%
|
$366.1m
+35.36%
|
$416.9m
+13.87%
|
|
| Research and Development Expense | $741k | $3.2m | $7.8m | $15.6m | $17.9m | $27.9m | $42.5m | $46.4m | $53.6m | $58.0m | $59.2m | |
| General and Administrative Expense | $402k | $1.6m | $4.2m | $6.5m | $15.1m | $40.4m | $77.7m | $98.4m | $113.7m | $146.7m | — | |
| Operating Lease, Expense | — | — | — | — | $756k | $1.3m | — | — | — | — | — | |
| Operating Expenses | $1.1m | $4.8m | $11.9m | $22.1m | $33.0m | $68.3m | $145.2m | $160.4m | $224.8m | $227.8m | $219.1m | |
| Operating Income (Loss) | ($1.1m) |
($4.8m)
-317.50%
|
($11.9m)
-149.71%
|
($22.1m)
-85.31%
|
($33.0m)
-49.45%
|
($68.3m)
-106.90%
|
($145.2m)
-112.66%
|
($109.7m)
+24.43%
|
$65.7m
+159.87%
|
$161.3m
+145.52%
|
$197.8m
+22.60%
|
|
| Interest Expense | — | — | — | — | — | $1.5m | $0 | $0 | — | — | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | $2k | $8k | $4k | $169k | $565k | $1.4m | $828k | ($1.2m) | — | |
| Gain (Loss) Related to Litigation Settlement | — | — | — | — | — | $560k | — | — | — | $0 | — | |
| Unrealized gain (loss) on available-for-sale securities, net of tax | — | — | $2k | $8k | ($4k) | ($169k) | ($565k) | $1.4m | ($828k) | $642k | — | |
| Interest and other income, net | — | — | $1.0m | $3.0m | $832k | $197k | $5.2m | $22.6m | $29.7m | $28.2m | — | |
| Interest Income (Expense), Nonoperating, Net | — | — | — | — | — | — | — | — | $29.7m | $28.2m | $28.9m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $1.1m | $4.8m | $11.9m | $22.1m | $33.0m | $68.3m | ($140.0m) | $12.9m | $95.4m | $189.5m | $226.6m | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.0m | $6.2m | ($15.4m) | ($14.8m) | |
| Net Income (Loss) Attributable to Parent | ($1.1m) |
($7.9m)
-588.70%
|
($10.9m)
-37.49%
|
($19.1m)
-75.30%
|
($32.2m)
-68.52%
|
($69.6m)
-116.28%
|
($140.0m)
-101.20%
|
$10.9m
+107.81%
|
$89.2m
+715.58%
|
$204.8m
+129.74%
|
$241.5m
+17.88%
|
|
| Earnings Per Share, Basic | — | — | — | — | ($1.71) | ($3.13) | ($5.49) | $0.40 | $3.12 | $7.08 | $8.27 | |
| Earnings Per Share, Diluted | ($1.31) | ($1.48) | ($0.97) | ($1.20) | ($1.71) | ($3.13) | ($5.49) | $0.39 | $3.00 | $6.84 | $7.98 | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | $18.8m | 22.2m | 25.5m | 27.2m | 28.6m | 28.9m | 29.2m | |
| Basic (in shares) | — | — | — | — | $18.8m | $22.2m | $25.5m | $27.2m | $28.6m | $28.9m | $29.2m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | 22.2m | 25.5m | 27.8m | 29.7m | 30.0m | 30.3m | |
| Additional Financial Items | ||||||||||||
| Realized Investment Gains (Losses) | — | — | — | — | — | — | $570k | $5.1m | $6.1m | $6.0m | — | |
| Litigation settlement | — | — | — | — | $0 | $0 | $25.0m | $12.5m | $37.5m | $0 | — | |
| Income (loss) from operations | ($1.1m) |
($4.8m)
-317.50%
|
($11.9m)
-149.71%
|
($22.1m)
-85.31%
|
($33.0m)
-49.45%
|
($68.3m)
-106.90%
|
($145.2m)
-112.66%
|
($109.7m)
+24.43%
|
$65.7m
+159.87%
|
$161.3m
+145.52%
|
$197.8m
+22.60%
|
|
| Gain from sale of priority review voucher | — | — | — | — | — | $0 | $0 | $100.0m | $0 | $0 | — | |
| Foreign currency translation | — | — | — | — | — | — | — | ($66k) | ($388k) | $684k | — | |
| Comprehensive income | — | — | ($10.9m) | ($19.1m) | ($32.2m) | ($69.7m) | ($140.5m) | $12.3m | $88.3m | $206.2m | — |